Industry News

Liberty Property Trust is under agreement to sell much of its holdings in the Great Valley Corporate Center, the pioneering Chester County business park that transformed Malvern and made the developer into a major regional office landlord. The company is selling 26 Great Valley properties, accounting for over a million square feet of office and light-industrial space, to Horsham-based Workspace Property Trust, Liberty announced Monday. The properties are part of a..."/>
Liberty Property Trust to sell most Great Valley Corporate Center holdings in milestone for company [The Philadelphia Inquirer]
Biocon Ltd's shares have gained 65% since the start of this fiscal year. The stock declined a bit in early July but improved after its results last week, and is up by 17% since 21 July. While it posted a good set of numbers, that alone did not cause the recent bump."/>
Biocon: hope in the pipeline [Mint, New Delhi]
Express Scripts Holding Co., the nation's largest pharmacy benefit manager, reported prescriptions fell slightly during the second quarter along with revenue. Total adjusted claims declined to 315 million for the quarter ended June 30, compared with 321 million during the year-earlier period. Revenue dipped to $25.2 billion compared with $25.4 billion during the year-earlier period."/>
BRIEF: Express Scripts reports slight dip in prescriptions during 2Q, narrows guidance [St. Louis Post-Dispatch]
FibroGen, Inc., today announced the dosing of the first patient in Phase 3 trials in Japan of roxadustat for treatment of anemia in chronic kidney disease, which triggered a $10 million milestone payment from Astellas to FibroGen. The initiation of Phase 3 studies in Japan follows the positive results from two Phase 2 studies in Japan of roxadustat in CKD patients on dialysis and in CKD patients not on dialysis.."/>
Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan
Luye Pharma Group Ltd. announces its agreement to acquire the TDS business from Acino, through the purchase of the entire issued share capital of Acino AG and Acino Supply AG for EUR245, 000,000. The Target Group is a Europe based global leader in advanced transdermal drug delivery systems and it is one of the largest independent TDS manufacturers in Europe. The TDS business includes the business of developing, producing and distributing..."/>
Luye Pharma Takes a Milestone Step Forward; Proposed Acquisition of Acino's TDS Business
Genmab A/S announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for DARZALEX (r) injection in..."/>
Daratumumab Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration in Combination with Standard of Care Regimens for Previously Treated Multiple Myeloma
Luye Pharma Group Ltd. announces its agreement to acquire the TDS business from Acino, through the purchase of the entire issued share capital of Acino AG and Acino Supply AG for EUR245, 000,000. The Target Group is a Europe based global leader in advanced transdermal drug delivery systems and it is one of the largest independent TDS manufacturers in Europe. The TDS business includes the business of developing, producing and distributing therapeutic..."/>
Luye Pharma Takes a Milestone Step Forward; Proposed Acquisition of Acino's TDS Business
MB Financial Inc. will replace First Niagara Financial Group Inc. in the S&P MidCap 400, BioTelemetry Inc. will replace MB Financial in the S&P SmallCap 600. S&P 500 constituent KeyCorp is acquiring First Niagara Financial Group in a deal expected to be completed soon..."/>
MB Financial to Join S&P MidCap 400; BioTelemetry and Raven Industries to Join S&P SmallCap 600
Champions Oncology, a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year quarter ended April 30, 2016, on Thursday, July 28, 2016, before market open. The company will host a conference call to discuss the results that day at 8:30 a.m. EDT."/>
Champions Oncology to Announce Year-End 2016 Financial Results on Thursday, July 28, 2016
Relypsa Inc. in connection with the proposed acquisition of the Company by Galenica Group. On July 21, 2016, the Company announced that it had reached a definitive agreement for Galenica to acquire all outstanding shares of RLYP in a transaction valued at $1.53 billion. Under the terms of the agreement, RLYP shareholders..."/>
Relypsa Inc. Acquisition May Not Be in the Best Interests of RLYP Shareholders
CryoLife, Inc., a leading medical device and tissue processing company focused on..."/>
CryoLife Reports Second Quarter 2016 Financial Results
DURECT Corporation's second quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Monday, August 1, 2016 at 4:30 pm Eastern Time. A live audio webcast of the presentation will be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast,..."/>
DURECT Corporation Invites You to Join its Second Quarter 2016 Earnings Conference Call
Brookdale Senior Living Inc. announced today that it plans to release its second quarter 2016 financial results after the market closes on Monday, August 8, 2016. The Company has also scheduled a conference call to discuss the results on Tuesday, August 9, 2016 at 10:00 AM ET. The conference call can be accessed by dialing 900-2996 or 643-2685 ten minutes prior to the scheduled start and referencing the "Brookdale Senior Living Second..."/>
Brookdale Announces Second Quarter 2016 Release and Earnings Call
Enanta Pharmaceuticals, Inc.,, a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral..."/>
Enanta Announces the U.S. Food and Drug Administration has approved AbbVie’s New, Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C Virus
Connecture, Inc., a provider of web-based information systems used to create health insurance marketplaces, will release its 2016 second quarter financial results on Monday, August 8, after market close and will host a conference call to follow at 5:00 p.m. Eastern Time.. Shareholders and interested participants who would like to listen to a live broadcast of the conference call may dial 930-8068 or 336-8043 and reference participant code..."/>
Connecture to Release 2016 Second Quarter Financial Results on August 8, 2016
AbbVie, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration has approved a New Drug Application for VIEKIRA XR™ extended-release tablets. VIEKIRA XR is a once-daily, extended-release co-formulation of the active ingredients in VIEKIRA PAK ® and is for the treatment of patients with chronic genotype 1 hepatitis C virus infection, including those with compensated cirrhosis."/>
AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
Nevro Corp., a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it will release financial results for the second quarter of 2016 after market close on Monday, August 8, 2016. Company management will host a conference call beginning at 1:30 p.m. Pacific Time on Monday, August 8, 2016.. Investors interested in listening to the conference call..."/>
Nevro to Report Operating Results for the Second Quarter 2016
RTI Surgical, Inc., a leading global surgical implant company, announced that a peer-reviewed, pre-clinical study titled Multipotent adult progenitor cells on an allograft scaffold facilitate the bone repair process has been published in the latest edition of the Journal of Tissue Engineering. The pre-clinical study, conducted by Amanda LoGuidice, PhD., used similar materials to..."/>
RTI Surgical® Continues to Advance Science Behind Allograft Implantation
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that it will report its 2016 second quarter financial and operating results after the close of U.S. financial markets on Wednesday, August 3, 2016. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time to discuss the results and to provide a corporate update.. To participate in the call, please dial 779-9075 or..."/>
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update
Eagle Pharmaceuticals, Inc. announced today that the Company will release its 2016 second quarter financial results on Tuesday, August 9, 2016, before the market opens. Scott Tarriff, President and Chief Executive Officer, and David E. Riggs, Chief Financial Officer, will host a conference call to discuss the results as follows:. A replay of the conference call will be available for one week after the call's completion by dialing 800-388-6509 or..."/>
Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2016 Financial Results on August 9, 2016
BioScrip, Inc. announced today that the Company will release its 2016 second quarter financial results on Monday, August 8, 2016, before the opening of the U.S. financial markets.. Richard M. Smith, President and Chief Executive Officer, and Jeffrey M. Kreger, Senior Vice President, Chief Financial Officer and Treasurer, will conduct a conference call as follows:. A replay of the conference call will be available for one week after the call's completion by dialing..."/>
BioScrip To Host 2016 Second Quarter Results Call
Phibro Animal Health Corporation today declared a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on September 28, 2016, to stockholders of record at the close of business on September 7, 2016.. About Phibro Animal Health Corporation. Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and..."/>
Phibro Animal Health Corporation Declares Quarterly Dividend

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials738 Articles
Consumer Discretionary651 Articles
Information Technology640 Articles
Industrials478 Articles
Health Care419 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.